BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 23386069)

  • 1. Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature.
    Adly G; Plakogiannis R
    Ann Pharmacother; 2013 Feb; 47(2):e8. PubMed ID: 23386069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
    Sung JJ; Lau JY; Ching JY; Wu JC; Lee YT; Chiu PW; Leung VK; Wong VW; Chan FK
    Ann Intern Med; 2010 Jan; 152(1):1-9. PubMed ID: 19949136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
    Chan FKL; Ching JYL; Tse YK; Lam K; Wong GLH; Ng SC; Lee V; Au KWL; Cheong PK; Suen BY; Chan H; Kee KM; Lo A; Wong VWS; Wu JCY; Kyaw MH
    Lancet; 2017 Jun; 389(10087):2375-2382. PubMed ID: 28410791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
    Chan FK; Chung SC; Suen BY; Lee YT; Leung WK; Leung VK; Wu JC; Lau JY; Hui Y; Lai MS; Chan HL; Sung JJ
    N Engl J Med; 2001 Mar; 344(13):967-73. PubMed ID: 11274623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S; Ittel TH; Wietholtz H
    Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy.
    Casado Arroyo R; Polo-Tomas M; Roncalés MP; Scheiman J; Lanas A
    Heart; 2012 May; 98(9):718-23. PubMed ID: 22523056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal safety of low-dose aspirin.
    Cryer B
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S701-8. PubMed ID: 12512737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries.
    Mo C; Sun G; Lu ML; Zhang L; Wang YZ; Sun X; Yang YS
    World J Gastroenterol; 2015 May; 21(17):5382-92. PubMed ID: 25954113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summaries for patients. Benefits and risks of continuing aspirin in patients with peptic ulcer bleeding.
    Ann Intern Med; 2010 Jan; 152(1):I-20. PubMed ID: 19949137
    [No Abstract]   [Full Text] [Related]  

  • 13. New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
    Hsu PI
    J Gastroenterol Hepatol; 2012 Apr; 27(4):654-61. PubMed ID: 22283743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid clinicians in practice.
    Lanas A; Polo-Tomás M; Casado-Arroyo R
    Aliment Pharmacol Ther; 2013 Apr; 37(7):738-48. PubMed ID: 23413984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies to reduce the GI risks of antiplatelet therapy.
    Scheiman JM
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
    Peura DA; Wilcox CM
    Postgrad Med; 2014 Jan; 126(1):87-96. PubMed ID: 24393755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
    Laine L
    Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice.
    Lanas A
    Expert Opin Drug Saf; 2011 Jan; 10(1):45-54. PubMed ID: 20645883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A; Moayyedi P; Hunt R;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal drug therapy after aspirin-induced upper gastrointestinal bleeding.
    Struijk M; Postma DF; van Tuyl SA; van de Ree MA
    Eur J Intern Med; 2012 Apr; 23(3):227-30. PubMed ID: 22385878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.